Wilkinson Blanc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nordic Nanovector Provides Update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma News provided by Share this article Share this article OSLO, Norway, Aug. 3, 2021 /PRNewswire/ Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin ® ( 177Lu lilotomab satetraxetan) in 3 rd-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL). The Company, having reviewed the recent rate of patient recruitment in discussion with its clinical advisors and in light of the continuing impact from the COVID pandemic, now anticipates the preliminary three-month data readout from PARADIGME during the first half of 2022.

Christine wilkinson blancFrazer hall davidMalene brondbergNordic nanovectorWilkinson blancChief medical officerDavid dibleSecurities tradingகிறிஸ்டின் வில்கின்சன் வெற்றுஃப்ரேசர் மண்டபம் டேவிட்வில்கின்சன் வெற்றுதலைமை மருத்துவ அதிகாரிடேவிட் டிபிலேபத்திரங்கள் வர்த்தக